AllSci News
HAYA's HTX-001 targets cardiac fibrosis through WISPER lncRNA reprogramming in nHCM patients
HAYA Therapeutics has dosed the first cohort in the Phase I/IIa clinical trial of HTX-001, an antisense oligonucleotide targeting WISPER lncRNA in patients...
PharmAla Biotech grants Jupiter Neuro US rights to ALA-002 MDMA therapeutic for USD 100m
PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF, Toronto) has signed a term sheet to grant Jupiter Neurosciences (Nasdaq: JUNS, Jupiter, Florida) exclusive,...
Eli Lilly adds non-viral genetic meds platform via USD 202m Engage Bio acquisition
Eli Lilly has acquired San Carlos, California-based Engage Biologics Inc. for up to USD 202 million in cash, adding the company's Tethosome non-viral DNA...
Dyne Therapeutics initiates Phase III FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy
Dyne Therapeutics (Nasdaq: DYN) has announced the initiation of the Phase III FORZETTO trial of zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular...
Remepy's drug-software combo produces significant symptoms reduction in Phase IIa Parkinson's disease trial
Remepy reported Phase IIa clinical trial results for Hybridopa (levodopa/carbidopa plus DopApp), its drug-software combination for Parkinson's disease,...
Forlong Bio secures USD 17.5m in Pre-B funding for cytokine pipeline advancement
Suzhou-based Forlong Biotechnology has closed a Series Pre-B financing round of approximately RMB 120 million (USD 17.5 million) to advance its IL-15 and...
Qiagen and Nvidia integrate knowledge graph infrastructure with BioNeMo platform for AI drug discovery
Qiagen (NYSE: QGEN; Frankfurt Prime Standard: QIA), headquartered in Venlo, Netherlands, and Nvidia have announced a collaboration integrating Nvidia’s accelerated computing infrastructure…
Exelixis and Merck expand zanzalintinib collaboration into resected colorectal cancer
Exelixis (Nasdaq: EXEL), based in Alameda, California, and Merck announced a clinical development collaboration to evaluate zanzalintinib in combination with Keytruda Qlex…
Pfizer's 25vPnC pneumococcal vaccine shows superior serotype 3 responses in Phase II pediatric study
Pfizer (NYSE: PFE) reported Phase II results for its 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in healthy infants, with...
BMS shakes with Anthropic to deploy Claude Enterprise across global pharma operations
Bristol Myers Squibb (BMS; NYSE: BMY, Princeton, NJ) and Anthropic announced a strategic agreement to deploy Claude AI as the company’s shared…
Bayer’s Hyrnuo gains FDA Priority Review for sBLA in first-line NSCLC
Bayer announced receipt of US FDA Priority Review for a supplemental New Drug Application (sNDA) for Hyrnuo (sevabertinib), an oral reversible HER2/EGFR…
IntraBio aiming Aqneursa as first ever treatment for ataxia-telangiectasia
IntraBio files for AQNEURSA approval in ataxia-telangiectasia, seeking first-ever treatment for the rare neurological disease
Gladstone Institutes receives USD 2m NIAID award for AI-guided phage therapy development
Gladstone Institutes has received a USD 2 million NIAID P01 award to establish the PhAIge Therapy Center, a multi-project preclinical program applying...
UCSD receives USD 2.5m NIDA grant for Brain-FRAMe HIV research program
University of California, San Diego has received a USD 2.5 million RM1 grant from the National Institute on Drug Abuse to launch Brain-FRAMe, a...
Roche and Medicines Patent Pool expand baloxavir marboxil access across 129 low- and middle-income countries
Roche (SIX: ROG) and the Medicines Patent Pool (MPP) announced the signing of a voluntary licence agreement covering baloxavir marboxil (Xofluza), Roche’s…
The AllSci Brief
Systematic R&D and deal news. Daily.